Detalhe da pesquisa
1.
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models.
Haematologica
; 106(4): 1034-1046, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32414851
2.
Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer.
Bioorg Med Chem Lett
; 50: 128335, 2021 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34425201
3.
Discovery of a C-8 hydroxychromene as a potent degrader of estrogen receptor alpha with improved rat oral exposure over GDC-0927.
Bioorg Med Chem Lett
; 29(16): 2090-2093, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31311734
4.
Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha.
Bioorg Med Chem Lett
; 29(7): 905-911, 2019 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30732944
5.
Physiologically based pharmacokinetic model for composite nanodevices: effect of charge and size on in vivo disposition.
Pharm Res
; 29(9): 2534-42, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22688900
6.
The United States COVID-19 Forecast Hub dataset.
Sci Data
; 9(1): 462, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35915104
7.
GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.
J Med Chem
; 64(16): 11841-11856, 2021 08 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34251202
8.
Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer.
ACS Med Chem Lett
; 11(6): 1342-1347, 2020 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32551022